Advice
Following an abbreviated submission Accepted for use in NHSScotland.
Stalevo® for the treatment of patients with Parkinson’s disease and end of dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor treatment.
This combination preparation allows administration of a single tablet incorporating ingredients that are routinely combined for the indication described above. This may improve convenience to the patient. Depending on the doses and formulations being replaced, conversion to the combination may result in a modest increase in cost or (less commonly) a cost saving.
Download detailed advice18KB (PDF)
Medicine details
- Medicine name:
- Levodopa, carbidopa and entacapone (Stalevo)
- SMC ID:
- 85/03
- Indication:
- Parkinson's disease and end of dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor treatment
- Pharmaceutical company
- Orion Pharma (UK) Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 January 2004